At a glance
ClinicalIndex Comparison Record- ✓Age 35 years or older
- ✓BMI ≥30 kg/m² or BMI ≥27 kg/m² if metabolic syndrome present
- ✓Metabolic syndrome defined as ≥3 of: waist circumference >102 cm (men) or >88 cm (women), triglycerides >150 mg/dL or on treatment, HDL <40 mg/dL (men) or <50 mg/dL (women), BP >130/85 mmHg or on treatment, fasting glucose >100 mg/dL
- ✓Able to provide informed consent
- ✕Prior GLP-1 receptor agonists (liraglutide, exenatide, others), DPP-4 inhibitors, or insulin within last 3 months
- ✕Any anti-obesity drug or supplement within 1 month prior to screening
- ✕Weight fluctuation >5% within 3 months prior to screening
- ✕History of diabetes mellitus (type 1 or 2) or current anti-diabetes medication
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease
In Brief
A Phase 4 clinical trial evaluating Liraglutide and Placebo for Obesity, Visceral and 2 related conditions. Completed, enrolled 235 participants across 1 site.
Detailed Summary
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks on-treatment.
Study Details
Timeline
Interventions
Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.